Business
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
CARLSBAD, Calif., May 05, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/73599f76f4ec60f4750f23884ab6cde8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1jIDK6F94q.hz2rIh2buHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OQ--/https://media.zenfs.com/en/business-wire.com/73599f76f4ec60f4750f23884ab6cde8","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/mccNN1kaDX8tErMdQIORIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY-/https://media.zenfs.com/en/business-wire.com/73599f76f4ec60f4750f23884ab6cde8","width":1200,"height":248}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., May 05, 2026--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update.","length":655,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast","length":27,"tagName":"p"},{"type":"text","content":"Interested parties may access the conference call on May 12, 2026, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call" (Conference ID: 9229676). A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through May 19, 2026, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 9229676.","length":551,"tagName":"p"},{"type":"text","content":"About Lineage Cell Therapeutics, Inc.","length":37,"tagName":"p"},{"type":"text","content":"Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious ...